Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction

被引:87
|
作者
Schiattarella, Gabriele G. [1 ,2 ,3 ,4 ,5 ]
Altamirano, Francisco [1 ]
Kim, Soo Young [1 ]
Tong, Dan [1 ]
Ferdous, Anwarul [1 ]
Piristine, Hande [1 ]
Dasgupta, Subhajit [1 ]
Wang, Xuliang [1 ]
French, Kristin M. [1 ]
Villalobos, Elisa [1 ]
Spurgin, Stephen B. [6 ]
Waldman, Maayan [1 ]
Jiang, Nan [1 ]
May, Herman I. [1 ]
Hill, Theodore M. [1 ]
Luo, Yuxuan [1 ]
Yoo, Heesoo [1 ]
Zaha, Vlad G. [1 ,7 ,8 ,9 ]
Lavandero, Sergio [1 ,10 ,11 ]
Gillette, Thomas G. [1 ]
Hill, Joseph A. [1 ,12 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med Cardiol, Dallas, TX 75390 USA
[2] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy
[3] Charite Univ Med Berlin, Ctr Cardiovasc Res CCR, Dept Cardiol, Berlin, Germany
[4] DZHK German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany
[5] Helmholtz Assoc MDC, Translat Approaches Heart Failure & Cardiometab D, Max Delbruck Ctr Mol Med, Berlin, Germany
[6] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA
[7] Univ Texas Southwestern Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA
[8] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc, Dallas, TX 75390 USA
[9] Parkland Hlth & Hosp Syst, Dallas, TX USA
[10] Univ Chile, Adv Ctr Chron Dis ACCDiS, Fac Chem & Pharmaceut Sci, Santiago, Chile
[11] Univ Chile, Fac Med, Santiago, Chile
[12] Univ Texas Southwestern Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA
关键词
UNFOLDED PROTEIN RESPONSE; INSULIN-RESISTANCE; TRANSCRIPTION FACTORS; PRESSURE-OVERLOAD; QUALITY CONTROL; PHENOTYPE; OBESITY; ACTIVATION; HOMEOSTASIS; METABOLISM;
D O I
10.1038/s41467-021-21931-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Heart failure with preserved ejection fraction (HFpEF) is now the dominant form of heart failure and one for which no efficacious therapies exist. Obesity and lipid mishandling greatly contribute to HFpEF. However, molecular mechanism(s) governing metabolic alterations and perturbations in lipid homeostasis in HFpEF are largely unknown. Here, we report that cardiomyocyte steatosis in HFpEF is coupled with increases in the activity of the transcription factor FoxO1 (Forkhead box protein O1). FoxO1 depletion, as well as over-expression of the Xbp1s (spliced form of the X-box-binding protein 1) arm of the UPR (unfolded protein response) in cardiomyocytes each ameliorates the HFpEF phenotype in mice and reduces myocardial lipid accumulation. Mechanistically, forced expression of Xbp1s in cardiomyocytes triggers ubiquitination and proteasomal degradation of FoxO1 which occurs, in large part, through activation of the E3 ubiquitin ligase STUB1 (STIP1 homology and U-box-containing protein 1) a novel and direct transcriptional target of Xbp1s. Our findings uncover the Xbp1s-FoxO1 axis as a pivotal mechanism in the pathogenesis of cardiometabolic HFpEF and unveil previously unrecognized mechanisms whereby the UPR governs metabolic alterations in cardiomyocytes. Heart failure with preserved ejection fraction (HFpEF) is a global, major health issue for which no effective therapies are available. Here, the authors discover that the interplay between two transcription factors, Xbp1s and FoxO1, is critical for metabolic adaptation and lipid handling in HFpEF-stressed cardiomyocytes.
引用
收藏
页数:14
相关论文
共 40 条
  • [31] Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
    Sokos, George G.
    Nikolaidis, Lazaros A.
    Mankad, Sunil
    Elahi, Dariush
    Shannon, Richard P.
    JOURNAL OF CARDIAC FAILURE, 2006, 12 (09) : 694 - 699
  • [32] Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure STEPping Across the Ejection Fraction Divide
    Vaduganathan, Muthiah
    Ostrominski, John W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (22) : 2097 - 2100
  • [33] New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review
    Jalil, Jorge E.
    Gabrielli, Luigi
    Ocaranza, Maria Paz
    MacNab, Paul
    Fernandez, Rodrigo
    Grassi, Bruno
    Jofre, Paulina
    Verdejo, Hugo
    Acevedo, Monica
    Cordova, Samuel
    Sanhueza, Luis
    Greig, Douglas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (08)
  • [34] Performance of the H2FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: A report from the Japanese multicenter registry
    Tada, Atsushi
    Nagai, Toshiyuki
    Omote, Kazunori
    Iwano, Hiroyuki
    Tsujinaga, Shingo
    Kamiya, Kiwamu
    Konishi, Takao
    Sato, Takuma
    Komoriyama, Hirokazu
    Kobayashi, Yuta
    Takenaka, Sakae
    Mizuguchi, Yoshifumi
    Sato, Tomoya
    Yamamoto, Kazuhiro
    Yoshikawa, Tsutomu
    Saito, Yoshihiko
    Anzai, Toshihisa
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 342 : 43 - 48
  • [35] The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?
    Karakasis, Paschalis
    Fragakis, Nikolaos
    Patoulias, Dimitrios
    Theofilis, Panagiotis
    Sagris, Marios
    Koufakis, Theocharis
    Vlachakis, Panayotis K.
    Rangraze, Imran Rashid
    El Tanani, Mohamed
    Tsioufis, Konstantinos
    Rizzo, Manfredi
    BIOMEDICINES, 2024, 12 (09)
  • [36] TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study
    van de Bovenkamp, A. A.
    Bakermans, A. J.
    Allaart, C. P.
    Nederveen, A. J.
    Kok, W. E. M.
    van Rossum, A. C.
    Handoko, M. L.
    NETHERLANDS HEART JOURNAL, 2020, 28 (06) : 312 - 319
  • [37] Impact of Body Mass Index on outcomes in hospitalized heart failure patients with reduced versus preserved ejection fraction: a 1,699,494-individual analysis from the United States National Inpatient Sample
    Ansari, Saad A.
    Suheb, Mahammed Z.
    Rashid, Muhammad
    Maqsood, Muhammad H.
    Rashid, Ahmed M.
    Javaid, Syed S.
    Siddiqi, Ahmed K.
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2023, : 141 - 151
  • [38] Evaluation of the effects of different treatment modalities on angiogenesis in heart failure patients with reduced/midrange ejection fraction via VEGF and sVEGFR-1
    Erturk, Ismail
    Saglam, Kenan
    Elasan, Sadi
    Aykan, Musa B.
    Acar, Ramazan
    Yesildal, Fatih
    Aydin, Fevzi N.
    Ozgurtas, Taner
    SAUDI MEDICAL JOURNAL, 2018, 39 (10) : 1028 - 1034
  • [39] Metabolic Profiling Identifies 1-MetHis and 3-IPA as Potential Diagnostic Biomarkers for Patients With Acute and Chronic Heart Failure With Reduced Ejection Fraction
    Kretzschmar, Tom
    Westphal, Julian
    Neugebauer, Sophie
    Wu, Jasmine M. F.
    Zeller, Max
    Bogoviku, Jurgen
    Bekhite, Mohamed M.
    Bekfani, Tarek
    Schlattmann, Peter
    Kiehntopf, Michael
    Franz, Marcus
    Schulze, P. Christian
    CIRCULATION-HEART FAILURE, 2024, 17 (01) : E010813
  • [40] Global work index by non-invasive pressure-strain loops: a novel parameter to assess left ventricular performance in the early stages of heart failure with preserved or mid-range ejection fraction after acute myocardial infarction
    Tomoaia, Raluca
    Beyer, Ruxandra Stefana
    Zdrenghea, Dumitru
    Dadarlat-Pop, Alexandra
    Cismaru, Gabriel
    Gusetu, Gabriel
    Rosu, Radu
    Serban, Adela
    Pop, Dana
    MEDICAL ULTRASONOGRAPHY, 2021, 23 (01) : 62 - 69